Skip to content
Technology
About us
Pipeline
News
Careers
Menu
Technology
About us
Pipeline
News
Careers
CONTACT
News
November 2, 2023
Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
Read more
November 2, 2023
Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
Read more
February 9, 2023
Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
Read more
February 9, 2023
Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
Read more
January 9, 2023
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
Read more
January 9, 2023
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
Read more
October 19, 2022
Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
October 19, 2022
Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
October 5, 2022
Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
Read more
October 5, 2022
Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
Read more
March 2, 2022
Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
March 2, 2022
Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
January 26, 2022
Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
January 26, 2022
Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
November 11, 2021
Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
Read more
November 11, 2021
Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
Read more
Icons
Technology
About us
Pipeline
News
Careers
Technology
About us
Pipeline
News
Careers
CONTACT